Veru (VERU) Income from Continuing Operations (2012 - 2026)
Veru (VERU) posted quarterly Income from Continuing Operations of 228000.0 for Q3 2025, up 97.44% year-over-year from 115478.0 in Q3 2024, and down 67.08% quarter-over-quarter from 136465.0 in Q2 2025.
Veru (VERU) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Veru (VERU) has reported Income from Continuing Operations for 14 consecutive years, with 228000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Income from Continuing Operations rose 97.44% year-over-year to 228000.0; the TTM figure through Mar 2026 stood at 364465.0 (up 98.04% YoY), while the FY2025 annual figure was 752498.0, up 102.01% from the prior year.
- Income from Continuing Operations eased to 228000.0 in Q3 2025 per VERU's latest filing, from 136465.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1251251.0 in Q4 2024 and bottomed at 42203529.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 11043198.0 across 5 years, with a median of 7451459.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 1211.42% — and 2024, when it surged 118.97%.
- Veru's Income from Continuing Operations stood at 6163476.0 in 2021, then tumbled by 397.02% to 30634016.0 in 2022, then surged by 78.47% to 6595252.0 in 2023, then soared by 118.97% to 1251251.0 in 2024, then plunged by 118.22% to 228000.0 in 2025.
- Business Quant data shows VERU's Income from Continuing Operations at 228000.0 in Q3 2025, 136465.0 in Q2 2025, and 585.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.29 Mn |
| Dec 31, 2025 | -194,000.00 |
| Sep 30, 2025 | -228,000.00 |
| Jun 30, 2025 | -136,465.00 |
| Mar 31, 2025 | -585.00 |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | -8.91 Mn |
| Jun 30, 2024 | -10.97 Mn |
| Mar 31, 2024 | -9.68 Mn |
| Dec 31, 2023 | -6.60 Mn |
| Sep 30, 2023 | -7.45 Mn |
| Jun 30, 2023 | -12.26 Mn |
| Mar 31, 2023 | -33.79 Mn |
| Dec 31, 2022 | -30.63 Mn |
| Sep 30, 2022 | -42.20 Mn |
| Jun 30, 2022 | -17.43 Mn |
| Mar 31, 2022 | -14.18 Mn |
| Dec 31, 2021 | -6.16 Mn |
| Sep 30, 2021 | -3.22 Mn |
| Jun 30, 2021 | -4.40 Mn |